Eledon Pharmaceuticals (ELDN) Common Equity (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Common Equity data on file, last reported at $44.8 million in Q1 2026.

• Quarterly Common Equity fell 23.98% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.8 million (down 23.98% YoY) and the FY2025 annual result came in at $81.1 million, up 29.85% from the prior year.
• Common Equity declined to $44.8 million in Q1 2026, from $81.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $156.3 million in Q1 2022 to a low of -$70.4 million in Q1 2024.
• A 5-year average of $46.8 million and a median of $44.8 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity sank 303.83% — and 2024, when it jumped 228.79%.
• Tracing ELDN's Common Equity over 5 years: stood at $23.8 million in 2022, then slumped by 303.83% to -$48.5 million in 2023, then jumped by 228.79% to $62.4 million in 2024, then increased by 29.85% to $81.1 million in 2025, then slumped by 44.79% to $44.8 million in 2026.
• The last three Common Equity figures came in at $44.8 million (Q1 2026), $81.1 million (Q4 2025), and $35.4 million (Q3 2025), per Business Quant data.